Search results for " inhibition"

showing 10 items of 435 documents

Cyclin dependent kinase-1 (Cdk-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (pdac)

2021

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, due to late diagnosis and limited treatment possibilities. Improved treatment for PDAC patients is warranted. Cyclin-dependent kinase 1 (CDK1) is a stimulator of cell cycle progression and its activity is regularly enhanced in pancreatic cancer cells. Therefore, CDK1 has been proposed as a novel drug target to treat patients with PDAC. This review describes the potential of CDK1 inhibition as a treatment for PDAC by outlining the molecular pathways influenced by CDK1 inhibition and new therapeutic strategies. Abstract The role of CDK1 in PDAC onset and development is two-fold. Firstly, since …

Cancer ResearchCell cycle checkpointendocrine system diseasesmedicine.medical_treatmentReviewenvironment and public healthTargeted therapyCyclin-dependent kinaseCancer stem cellPancreatic cancermedicineNovel treatmentCDK1 inhibitionRC254-282Cyclin-dependent kinase 1biologyChemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPDACPancreatic cancerCell cyclemedicine.diseaseenzymes and coenzymes (carbohydrates)Oncologybiology.proteinCancer researchStem cellbiological phenomena cell phenomena and immunityCell cycle regulation
researchProduct

Enhanced expression of the proto-oncogenes fos and raf in the rhabdomyosarcoma cell line BA-HAN-1C after differentiation induction with retinoic acid…

1990

BA-HAN-IC is a clonal rat rhabdomyosarcoma cell line consisting of proliferating mononuclear tumor cells, some of which spontaneously fuse to form terminally differentiated post-mitotic myotubes. Exposure of BA-HAN-IC cells to retinoic acid (RA) or N-methylformamide (NMF) resulted in a significant inhibition of proliferation (p less than 0.001) and in cellular differentiation, as evidenced by a significant increase in the creatine kinase (CK) activity (p less than 0.05) and the number of terminally differentiated post-mitotic myotubes (p less than 0.001). Furthermore, between 5% (NMF) and 30% (RA) of the mononuclear tumor cells exhibited ultrastructural features of rhabdomyogenic differenti…

Cancer ResearchCellular differentiationRetinoic acidAntineoplastic AgentsTretinoinBiologychemistry.chemical_compoundTretinoinProto-Oncogene ProteinsGene expressionRhabdomyosarcomamedicineTumor Cells CulturedAnimalsRNA MessengerRNA NeoplasmRhabdomyosarcomaFormamidesmedicine.diseaseMolecular biologyRatsGene Expression Regulation NeoplasticProto-Oncogene Proteins c-rafOncologychemistryCell cultureImmunologybiology.proteinCreatine kinaseGrowth inhibitionProto-Oncogene Proteins c-fosmedicine.drugInternational journal of cancer
researchProduct

Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.

1998

The roles of Bcl-2 protein and the protein ratio of Bcl-2/Bax in regulating cell growth in various lymphoma cell lines were examined. A dose-dependent decrease in Bcl-2 protein expression was observed in the different lymphomas incubated with lipid-incorporated bcl-2 antisense oligonucleotides (L-bcl-2). Growth inhibition was observed in a transformed follicular lymphoma (FL) cell line, which has the t(14;18) translocation and Bcl-2 protein overexpression. One of the mechanisms by which L-bcl-2 growth inhibition is mediated in these transformed FL cells might be through apoptotic induction, because the treated cells had an increased apoptotic index and showed the typical DNA fragmentation. …

Cancer ResearchFollicular lymphomaDown-RegulationApoptosisBiologychemistry.chemical_compoundDownregulation and upregulationProto-Oncogene ProteinsmedicineTumor Cells CulturedHumansLymphoma Follicularbcl-2-Associated X ProteinDrug CarriersCell growthHematologyOligonucleotides Antisensemedicine.diseaseLymphomaGene Expression Regulation NeoplasticCell Transformation NeoplasticOncologychemistryProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureLiposomesCancer researchDNA fragmentationGrowth inhibitionCell DivisionLeukemialymphoma
researchProduct

The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistan…

2013

The identification of novel compounds modulating the expression/activity of molecular targets downstream to BCR-ABL could be a new approach in the treatment of chronic myeloid leukemias (CMLs) resistant to imatinib or other BCR-ABL-targeted molecules. Recently, we synthesized a new class of substituted 2-(3,4,5-trimethoxybenzoyl)-2-N,N-dimethylamino-benzo[b]furans, and among these 3-iodoacetylamino-6-methoxybenzofuran-2-yl(3,5-trimethoxyphenyl)methanone (TR120) showed marked cytotoxic activity in BCR-ABL-expressing cells. Interestingly, TR120 was more potent than imatinib in cell growth inhibition and apoptosis induction in both BCR-ABL-expressing K562 and KCL22 cells. Moreover, it showed a…

Cancer ResearchFusion Proteins bcr-ablApoptosisPiperazinesSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundhemic and lymphatic diseasesSTAT5 Transcription FactorCytotoxic T cellPharmacology (medical)Cyclin D1STAT5biologyDrug SynergismCell cycleNeoplasm ProteinsGene Expression Regulation NeoplasticLeukemiaOncologyProto-Oncogene Proteins c-bcl-2BenzamidesImatinib MesylateGrowth inhibitionmedicine.drugbcl-X ProteinDown-RegulationAntineoplastic AgentsBone Marrow CellsResting Phase Cell CycleColony-Forming Units AssayBenzophenonesNecrosisCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansneoplasmsBenzofuransPharmacologyG1 PhaseImatinibBCR-ABL chronic myeloid leukemia imatinib resistance STAT5 tyrosine kinase inhibitorsmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGenes bcl-1Genes bcl-2PyrimidineschemistryApoptosisDrug Resistance NeoplasmSettore BIO/14 - FarmacologiaCancer researchbiology.proteinK562 CellsK562 cells
researchProduct

Lactate-induced inhibition of tumor cell proliferation.

1988

Abstract Culture medium that was recovered from tumor cell or fibroblast cultures during the plateau phase, and that was replenished by addition of glucose, glutamine, and serum and readjustment of pH had a distinct growth-inhibiting effect on monolayer cell cultures. The effect, which was not specific for a given cell strain, may be partially responsible for the "density inhibition" commonly observed in malignant cells grown in monolayer cultures. By modifying fresh growth media, it was shown that the growth inhibition observed can be partly attributed to the accumulation of lactate in the culture medium of plateau phase cells. This substance reduced the plating efficiency and the number o…

Cancer ResearchPlating efficiencyPlateau (mathematics)law.inventionchemistry.chemical_compoundMiceIn vivolawMonolayerTumor Cells CulturedMedicineAnimalsHumansRadiology Nuclear Medicine and imagingLactic AcidAmino AcidsRadiationbusiness.industryPetri dishCell biologyCulture MediaGlutamineOncologychemistryCell cultureImmunologyLactatesGrowth inhibitionbusinessCell DivisionInternational journal of radiation oncology, biology, physics
researchProduct

Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression

2015

As part of the Halifax Project, this review brings attention to the potential effects of environmental chemicals on important molecular and cellular regulators of the cancer hallmark of evading growth suppression. Specifically, we review the mechanisms by which cancer cells escape the growth-inhibitory signals of p53, retinoblastoma protein, transforming growth factor-beta, gap junctions and contact inhibition. We discuss the effects of selected environmental chemicals on these mechanisms of growth inhibition and cross-reference the effects of these chemicals in other classical cancer hallmarks.

Cancer ResearchReviewHazardous Substanceschemistry.chemical_compoundNeoplasmsAnimalsHumansMedicinebiologyAnimalbusiness.industryMedicine (all)Retinoblastoma proteinContact inhibitionCancerEnvironmental ExposureGeneral MedicineEnvironmental exposureEvasion (ethics)medicine.diseaseCell biologychemistryHazardous SubstanceImmunologyCancer cellbiology.proteinNeoplasmSignal transductionGrowth inhibitionbusinessHumanSignal TransductionCarcinogenesis
researchProduct

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

2018

Cancer Researchbiologybusiness.industryAfatiniblung cancer EGFR epidermal growth factor receptor inhibition resistancemedicine.diseaseEGFR Tyrosine Kinase InhibitorsGefitinibCancer researchbiology.proteinMedicinePharmacology (medical)OsimertinibEpidermal growth factor receptorErlotinibNon small cellbusinessLung cancermedicine.drug
researchProduct

Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast canc…

2015

Raf-1 kinase inhibitor protein (RKIP) is a tumor suppressor and metastasis inhibitor, which enhances drug-induced apoptosis of cancer cells. Downregulation of RKIP may be significant in the biology of highly aggressive and drug-resistant tumors, for example triple-negative breast cancers (TNBCs). Potential causes for the low levels of RKIP expressed by SUM 159 TNBC cells were investigated in the present study. Bisulphite modification, methylation specific-polymerase chain reaction (PCR) and a TransAM NF-κB assay were performed and the results suggested that various mechanisms, including methylation of the gene promoter, histone deacetylation and nuclear factor-κB (NF-κB) activation, but not…

Cancer Researchmedicine.drug_classCell growthtriple-negative breast cancer Raf-1 kinase inhibitor protein epigenetic changes microRNA-224 nuclear factor-κBHistone deacetylase inhibitorArticlesCell cycleBiologyMolecular biologyDemethylating agentchemistry.chemical_compoundTrichostatin AOncologychemistryCancer cellmedicineCancer researchGrowth inhibitionTranscription factormedicine.drug
researchProduct

The aryl hydrocarbon receptor (AhR) in the regulation of cell–cell contact and tumor growth

2010

The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor, which is activated by a large group of environmental pollutants including polycyclic aromatic hydrocarbons, dioxins and planar polychlorinated biphenyls. Ligand binding leads to dimerization of the AhR with aryl hydrocarbon receptor nuclear translocator and transcriptional activation of several xenobiotic phase I and phase II metabolizing enzymes, such as cytochrome P4501A1 and glutathione- S -transferase, respectively. Since phase I enzymes convert inert carcinogens to active genotoxins, the AhR plays a key role in tumor initiation. Besides this classical route, the AhR mediates tumor promotion and recent evide…

Cancer Researchmedicine.medical_specialtyAryl hydrocarbon receptor nuclear translocatorReviewsTumor initiationCell Communicationmedicine.disease_causeInternal medicineNeoplasmsmedicineCell AdhesionHomeostasisHumansTranscription factorbiologyCell CycleCell MembraneContact inhibitionMembrane ProteinsEpithelial CellsGeneral MedicineAryl hydrocarbon receptorEndocrinologyReceptors Aryl HydrocarbonTumor progressionbiology.proteinCancer researchTumor promotionCarcinogenesisCell DivisionSignal Transduction
researchProduct

TCDD-dependent downregulation of gamma-catenin in rat liver epithelial cells (WB-F344).

2002

TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is the most potent tumor promoter ever tested in rodents. Although it is known that most of the effects of TCDD are mediated by binding to the aryl hydrocarbon receptor (AHR), the mechanisms leading to tumor promotion still remain to be elucidated. Loss of contact-inhibition is a characteristic hallmark in tumorigenesis. In WB-F344 cells, TCDD induces a release from contact-inhibition manifested by a 2- to 3-fold increase in DNA-synthesis and the emergence of foci when TCDD (1 nM) is given to confluent cells. We focussed our interest on potential cell membrane proteins mediating contact-inhibition in WB-F344 cells, namely E-cadherin, alpha,- beta,-…

Cancer Researchmedicine.medical_specialtyPolychlorinated DibenzodioxinsTime FactorsOctoxynolBlotting WesternDetergentsDown-RegulationDownregulation and upregulationInternal medicinemedicineAnimalsFluorescent Antibody Technique IndirectCells Culturedbeta CateninConfluencybiologyReverse Transcriptase Polymerase Chain ReactionLiver NeoplasmsContact inhibitionEpithelial CellsDNAAryl hydrocarbon receptorActin cytoskeletonBlotting NorthernCadherinsCell biologyRatsCytoskeletal ProteinsEndocrinologyPhenotypeOncologyDesmoplakinsLiverMicroscopy FluorescenceCateninMutationbiology.proteinProteasome inhibitorCarcinogensTrans-ActivatorsTumor promotionEnvironmental Pollutantsgamma CateninCell Divisionalpha Cateninmedicine.drugInternational journal of cancer
researchProduct